NASDAQ:MYGNMyriad Genetics Stock Price, Forecast & News

Myriad Genetics' stock was trading at $14.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MYGN shares have increased by 4.8% and is now trading at $14.71. View which stocks have been mosted impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 3 sell ratings, 4 hold ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Myriad Genetics.

Myriad Genetics is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Myriad Genetics.

Myriad Genetics, Inc. (NASDAQ:MYGN) issued its earnings results on Thursday, February, 6th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.22 by $0.01. The business had revenue of $195.10 million for the quarter, compared to analysts' expectations of $209.61 million. Myriad Genetics had a positive return on equity of 5.42% and a negative net margin of 3.22%. The company's quarterly revenue was down 10.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.38 EPS. View Myriad Genetics' earnings history.

Myriad Genetics issued an update on its FY20 earnings guidance on Thursday, February, 6th. The company provided earnings per share guidance of approx $0.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.02. The company issued revenue guidance of approx $735 million, compared to the consensus revenue estimate of $807.66 million.

8 equities research analysts have issued twelve-month price objectives for Myriad Genetics' shares. Their forecasts range from $10.00 to $36.00. On average, they expect Myriad Genetics' stock price to reach $22.74 in the next year. This suggests a possible upside of 54.6% from the stock's current price. View analysts' price targets for Myriad Genetics.

News articles about MYGN stock have been trending very negative recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Myriad Genetics earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutMyriad Genetics.

Myriad Genetics saw a decrease in short interest during the month of March. As of March 13th, there was short interest totaling 11,772,600 shares, a decrease of 7.0% from the February 27th total of 12,660,000 shares. Based on an average daily trading volume, of 1,119,000 shares, the days-to-cover ratio is currently 10.5 days. Approximately 16.3% of the shares of the company are short sold. View Myriad Genetics' Current Options Chain.

Some companies that are related to Myriad Genetics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX), EXACT Sciences (EXAS), Ionis Pharmaceuticals (IONS) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Alibaba Group (BABA), Incyte (INCY), Kratos Defense & Security Solutions (KTOS), Gilead Sciences (GILD) and STMicroelectronics (STM).

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Myriad Genetics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.09%). Company insiders that own Myriad Genetics stock include Bernard Tobin, Dennis Langer, Gary A King, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Nicole Lambert, Ralph L Mcdade, Richard Bryan Riggsbee, Richard M Marsh and Walter Phd Gilbert. View institutional ownership trends for Myriad Genetics.

MYGN stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson, and Walter Phd Gilbert. View insider buying and selling activity for Myriad Genetics.

Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MYGN stock can currently be purchased for approximately $14.71.

Myriad Genetics has a market capitalization of $1.10 billion and generates $851.10 million in revenue each year. The company earns $4.60 million in net income (profit) each year or $1.29 on an earnings per share basis. Myriad Genetics employs 2,600 workers across the globe. View additional information about Myriad Genetics.

The official website for Myriad Genetics is http://www.myriad.com/.

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at 801-584-3600 or via email at [email protected]